Cangrelor is an intravenous, reversibly binding, P2Y12-receptor inhibitor with a rapid onset of action that yields a high level of receptor inhibition within minutes. The CHAMPION PHOENIX study has demonstrated that these pharmacodynamic properties yield superior efficacy compared with oral clopidogrel loading at the time of percutaneous coronary intervention.
